|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0240069,
umls-concept:C0470187,
umls-concept:C0966225,
umls-concept:C1140618,
umls-concept:C1174773,
umls-concept:C1261552,
umls-concept:C1280500,
umls-concept:C1960048,
umls-concept:C2587213,
umls-concept:C2603343
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-7-23
|
|
pubmed:abstractText |
Patients with severe persistent asthma despite GINA 2002 step 4 treatment are at risk for asthma-related morbidity and mortality. This study constitutes the Israeli arm of the international INNOVATE study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/omalizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1565-1088
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
472-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17642399-Adolescent,
pubmed-meshheading:17642399-Adrenal Cortex Hormones,
pubmed-meshheading:17642399-Adrenergic beta-Agonists,
pubmed-meshheading:17642399-Adult,
pubmed-meshheading:17642399-Aged,
pubmed-meshheading:17642399-Anti-Asthmatic Agents,
pubmed-meshheading:17642399-Antibodies, Anti-Idiotypic,
pubmed-meshheading:17642399-Antibodies, Monoclonal,
pubmed-meshheading:17642399-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17642399-Child,
pubmed-meshheading:17642399-Double-Blind Method,
pubmed-meshheading:17642399-Drug Therapy, Combination,
pubmed-meshheading:17642399-Emergency Service, Hospital,
pubmed-meshheading:17642399-Female,
pubmed-meshheading:17642399-Humans,
pubmed-meshheading:17642399-Israel,
pubmed-meshheading:17642399-Male,
pubmed-meshheading:17642399-Middle Aged,
pubmed-meshheading:17642399-Placebos,
pubmed-meshheading:17642399-Quality of Life,
pubmed-meshheading:17642399-Status Asthmaticus,
pubmed-meshheading:17642399-Time Factors,
pubmed-meshheading:17642399-Treatment Failure
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.
|
|
pubmed:affiliation |
Department of Medicine B, Kaplan Medical Center, Rehovot, Israel.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
